Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation

Fig. 2

Broad-spectrum inhibitory activity of EK1-peptides against infection mediated by mutant SARS-CoV-2 S proteins. a Antiviral activity of EK1 and EK1C4 against wild-type SARS-CoV-2 PsV infection on Caco2 cells. b, c Inhibitory activity of EK1 and EK1C4 against infection mediated by S protein of SARS-CoV-2 B.1.1.7 (b) and B.1.1.248 (c) variants on Caco2 cells. d–g Anti-SARS-CoV-2 efficacy of EK1 and EK1C4 on PsV infection mediated by the S protein with single mutations, including K417N (d), E484K (e), N501Y (f), or D614G (g), respectively on Caco2 cells. h-k Antiviral efficacy of EK1 and EK1C4 against PsV infection mediated by the S protein with combinational mutations, including K417N/ E484K (h), N501Y/ K417N (i) N501Y/E484K (j), and N501Y/ K417N/E484K (k), respectively, on Caco2 cells. Experiments were repeated twice, and the data are expressed as means ± SD

Back to article page